Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy-Reference-Cited by-同舟云学术

Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy

Published:2022-08 Issue: Volume:41 Page:122-128
ISSN:1553-8389
Container-title:Cardiovascular Revascularization Medicine
language:en
Short-container-title:Cardiovascular Revascularization Medicine

Author:

Hemetsberger Rayyan,Richardt Gert,Lahu Shqipdona,Valina Christian,Menichelli Maurizio,Abdelghani Mohammad,Wöhrle Jochen,Toelg Ralph,Witzenbichler Bernhard,Mankerious Nader,Liebetrau Christoph,Bernlochner Isabell,Hamm Christian W.,Allali Abdelhakim,Joner Michael,Fusaro Massimiliano,Xhepa Erion,Hapfelmeier Alexander,Kufner Sebastian,Sager Hendrik B.,Schüpke Stefanie,Laugwitz Karl-Ludwig,Schunkert Heribert,Neumann Franz-Josef,Kastrati Adnan,Cassese Salvatore

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference15 articles.

1. 2018 ESC/EACTS guidelines on myocardial revascularization;Neumann;Eur Heart J,2019

2. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation;Collet;Eur Heart J,2021

3. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial;Montalescot;Lancet,2009

4. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study;Cannon;Lancet,2010

5. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms;Buccheri;Expert Opin Drug Saf,2019